Skip to main content
. 2021 Dec 23;12:790072. doi: 10.3389/fphar.2021.790072

FIGURE 7.

FIGURE 7

Schematic diagram shows that LPS, as a ligand of TLR4, can activate TLR4/NF-kB pathway and NLRP3 inflammasome and then upregulate the level of IL-6, TNF-α, MCP-1, IFN-γ, IL-1β, and IL-18, promoting lung damage. QWZK could protect LPS-induced ALI via downregulating the expression of IL-6, TNF-α, MCP-1, IFN-γ, IL-1β, and IL-18. Its mechanism of action might inhibit TLR4/NF-kB pathway and NLRP3 inflammasome activation.